 YSPSL-0003 is an extension into 36 patients of the previous 12 patient pilot study YSPSL-0002 under an almost identical study protocol with extended inclusion criteria. Like YSPSL-0002, YSPSL-0003 is a single-center UCLA, randomized, placebo-controlled, double-blind study. Patients are randomly assigned to either active study drug Active group or placebo Control group prior to transplantation. The active study drug dose includes both a 1 mgkg IV infusion for the recipient and a 20 mg approximately 0.27 mgkg as an ex vivo flush. The doses are administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan; and the second infusion of 1 mgkg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Placebo of a volume equivalent to active study drug is prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of 10 units, receive an additional 1 mgkg IV infusion of study agent or placebo equivalent at the end of the transplant surgery. The InvestigatorSponsor is blinded to the treatment assignment for each patient. Randomization assignment is maintained by UCLAs clinical pharmacist. 